Which bone drug best prevents fractures after denosumab? new study aims to find out
NCT ID NCT07406685
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study compares two bone-strengthening drugs, ibandronate and zoledronic acid, given after stopping denosumab in postmenopausal women with osteoporosis. The goal is to see which drug better maintains bone density and prevents fractures. About 52 women aged 50-85 who took denosumab for 1-3 years will participate.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OSTEOPOROSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
National Taiwan University Hospital
Taipei, 100, Taiwan
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can discarded bone reveal the secrets to stronger bones?
- Could a common diabetes drug weaken your bones?
- A tastier calcium chew might boost bone Health—But does it work?
- Exercise program aims to steady the stance of osteoporosis patients
- Can a Bone-Strengthening infusion given right after hip surgery prevent a second break?
- Can a single dose of zoledronic acid safely treat bone loss in dialysis patients?